IceCure Granted New Patent in China for Its Cryogenic System Connector, Expanding Its Global IP Portfolio
The patent grant follows September 2026 approval to market ProSense and its associated cryoprobes in China.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
IceCure Medical (ICCM) has received a Chinese patent covering a connector used in its cryogenic technology platform for freezing tumors. The grant from the China National Intellectual Property Administration adds to a portfolio containing 42 patents across the United States, Europe, Great Britain, China and Japan.
The patent follows September 2026 approval from China's National Medical Products Administration to market ProSense and its associated cryoprobes in China. IceCure's patent portfolio covers its technology platform and innovations intended for current and future products.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Major pointSeptember 2026 regulatory approval permits marketing ProSense and its associated cryoprobes in China.
- Minor pointNew Chinese patent adds protection for a connector used in IceCure's cryogenic technology platform.
Negative
- None.
Key Figures
- Patent portfolio
- 42 patents
- Across the United States, Europe, Great Britain, China and Japan
Historical Context
-
China approved marketing ProSense and associated cryoprobes, establishing commercial authorization in the patent's market.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Newly Granted Patent Adds to IceCure's Portfolio of 42 Patents Across the
The patented connector is part of IceCure's cryogenic technology platform, and the patent grant follows a recent regulatory milestone for the Company in
IceCure's intellectual property portfolio contains 42 patents across
IceCure's intellectual property portfolio covers its technological platform and proprietary technologies, including innovations intended for incorporation into its current and future products. The Company continues to protect and expand its intellectual property portfolio across international markets, supporting its long-term technology strategy and protecting its proprietary innovations.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, as a safe and effective minimally invasive option to surgical tumor removal, with the primary focus areas being breast, kidney, bone and lung cancer. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and Asia.
ProSense® cryoablation became the first-and-only medical device cleared by the FDA for the local treatment of breast cancer in patients aged 70 years and older with biologically low-risk tumors ≤1.5 cm in size who are treated with adjuvant endocrine therapy, including patients who are not eligible for surgery.
Investor Relations:
Meir Peleg, CFO
+1-888-902-5716
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. For example, the Company is using forward-looking statements when it discusses the belief that the CNIPA patent grant expands the Company's global intellectual property portfolio and strengthens the protection of its proprietary cryogenic technologies in key international markets; the Company's potential future intellectual property portfolio and its long-term growth strategy and objectives. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2025 filed with the SEC on March 17, 2026, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/icecure-granted-new-patent-in-china-for-its-cryogenic-system-connector-expanding-its-global-ip-portfolio-302933250.html
SOURCE IceCure Medical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does IceCure's new Chinese patent cover?
The new patent covers a connector used in IceCure's cryogenic technology platform. It was granted by the China National Intellectual Property Administration.
How many patents does IceCure have following the Chinese patent grant?
IceCure's intellectual property portfolio contains 42 patents across the United States, Europe, Great Britain, China and Japan.